Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2

Journal of Nuclear Medicine

Volumn 55, Issue 3, 2014, Pages 439-445

  Kang, Fei ^a   Ma, Wenhui ^a   Ma, Xiaowei ^a   Shao, Yahui ^a   Yang, Weidong ^a   Chen, Xiaoyuan ^b   Li, Liwen ^a,c   Wang, Jing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c NORTHWEST UNIVERSITY   (China)

Author keywords

ADRB; Glucose metabolism; Hexokinase 2; Propranolol

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; ISOPRENALINE; PROPRANOLOL; UNCLASSIFIED DRUG; ADRB1 PROTEIN, HUMAN; ADRB2 PROTEIN, HUMAN; DIAGNOSTIC AGENT; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BROWN ADIPOSE TISSUE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOWN REGULATION; DRUG UPTAKE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY MECHANISM; RNA INTERFERENCE; TUMOR LOCALIZATION; 18F-FDG PET IMAGING; ADRB; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

18F-FDG PET IMAGING; ADRB; GLUCOSE METABOLISM; HEXOKINASE 2; PROPRANOLOL;

ANIMALS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; MICE; MICE, INBRED BALB C; POSITRON-EMISSION TOMOGRAPHY; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84899483686     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121327     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409-418.
3. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179- 1183.
4. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29:2635- 2644.
5. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2645-2652.
6. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1:628-638.
7. Lee JW, Shahzad MM, Lin YG, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009;15:2695-2702.
8. Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget. 2010;1:466-469.
9. Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010;120:1515-1523.
10. Sastry KS, Karpova Y, Prokopovich S, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem. 2007;282:14094-14100.
11. Nilsson MB, Armaiz-Pena G, Takahashi R, et al. Stress hormones regulate interleukin- 6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007;282:29919-29926.
12. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939- 944. (Pubitemid 44175146)
13. Armaiz-Pena GN, Allen JK, Cruz A, et al. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013;4:1403.
14. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
15. Dang CV. Links between metabolism and cancer. Genes Dev. 2012;26:877-890.
16. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
17. Jiang S, Zhang L-F, Zhang H-W, et al. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J. 2012;31:1985-1998.
18. Fang R, Xiao T, Fang Z, et al. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem. 2012;287:23227- 23235.
19. Mirbolooki MR, Constantinescu CC, Pan M-L, Mukherjee J. Quantitative assessment of brown adipose tissue metabolic activity and volume using 18F-FDG PET/CT and b3-adrenergic receptor activation. EJNMMI Res. 2011;1:30.
20. Wu C, Cheng W, Xing H, Dang Y, Li F, Zhu Z. Brown adipose tissue can be activated or inhibited within an hour before 18F-FDG injection: a preliminary study with MicroPET. J Biomed Biotechnol. 2011;2011:1-5.
21. Agrawal A, Nair N, Baghel NS. A novel approach for reduction of brown fat uptake on FDG PET. Br J Radiol. 2009;82:626-631.
22. Söderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging. 2007;34:1018-1022.
23. Parysow O, Mollerach AM, Jager V, Racioppi S, San Roman J, Gerbaudo VH. Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med. 2007;32:351-357.
24. Hu Y, Zhang Y, Venkitaramani DV, Lombroso PJ. Translation of striatal-enriched protein tyrosine phosphatase (STEP) after b1-adrenergic receptor stimulation. J Neurochem. 2007;103:531-541.
25. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996:140.
26. Glasner A, Avraham R, Rosenne E, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol. 2010; 184:2449-2457.
27. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003;80:63-70.
28. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70:7042-7052.
29. Szewczyk M, Richter C, Briese V, Richter DU. A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer. Anticancer Res. 2012;32:2133-2138.
30. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ. Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 2000;60:153-166.
31. Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2:797-809.
32. Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol. 2012;24:62-67.
33. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol. 2012;23:352-361.
34. Shoshan-Barmatz V, Golan M. Mitochondrial VDAC1: function in cell life and death and a target for cancer therapy. Curr Med Chem. 2012;19:714-735.
35. Guo-Qing P, Yuan Y, Cai-Gao Z, Hongling Y, Gonghua H, Yan T. A study of association between expression of hOGG1, VDAC1, HK-2 and cervical carcinoma. J Exp Clin Cancer Res. 2010;29:129.
36. Li Q. Chronic stress targets posttranscriptional mechanisms to rapidly upregulate a1C-subunit of Cav1.2b calcium channels in colonic smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2011;300:G154-G163.
37. Jiang X, Kenerson H, Aicher L, et al. The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Am J Pathol. 2008;172: 1748-1756.
38. Hamada K, Tomita Y, Qiu Y, et al. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med. 2008;22:699-705.
39. Hoshi M, Takada J, Oebisu N, Hata K, Ieguchi M, Nakamura H. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT. Arch Orthop Trauma Surg. 2012;132:1561-1568.
40. Kaira K, Endo M, Abe M, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-Dglucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746-3753.
41. Shim HK, Lee WW, Park SY, Kim H, Kim SE. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase- II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res. 2009;17:331-337.